Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

How Mission Bio is working to drive precision medicine

By Brian Buntz | June 10, 2022

Mission Bio Tapestri platform

Mission Bio’s Tapestri platform [Image courtesy of Mission Bio]

Mission Bio (San Francisco) is a growth-stage company spun out of the microfluidics lab at the University of California San Francisco (UCSF) in 2014.

“We have been commercial since late 2017,” said the company’s CEO, Yan Zhang, in a recent interview.

Initially focusing on oncology, Mission Bio has cast its gaze across precision medicine to cell and gene therapies. “We’re really in this incredible cross-section of oncology and cell and gene therapy,” Zhang said.

The company’s Tapestri platform can simultaneously provide:

  • Genotype and immunophenotype data from a single cell.
  • Detection of copy number variants (CNV).

Mission Bio has raised $110.9 million to date.

[This feature is a part of 2022’s Pharma 50 series.]

Zhang said that the company aims to “help drug developers take precision medicine to the next level.”

Mission Bio CEO - Mission Bio's Tapestri platform

Yan Zhang, CEO, Mission Bio – Mission Bio’s Tapestri platform

While there has been significant progress in precision medicine in the past two decades, physicians struggle to treat many cancers, genetic conditions and rare diseases.

Drug resistance remains a common barrier in cancer and genetic diseases. “The vast majority of so-called genetic diseases don’t have a cure,” Zhang noted.

Cystic fibrosis, an inherited disease, is an example. For patients with end-stage cystic fibrosis, lung transplantation remains one of the only treatment options.

Gene therapy offers significant potential for genetic-based diseases and cancer treatment, but discipline is required for the field to mature, Zhang noted. Gene therapy is the first therapeutic drug product that can live with patients for the rest of their lives. “Once you transfuse cells or make gene edits, it is irreversible,” Zhang said. “We have to have the ecosystem to support drug developers.”

The role of Mission Bio’s Tapestri platform in cell and gene therapy

Mission Bio says its Tapestri platform can help characterize and understand investigational cell and gene therapy products. In addition, Zhang said the platform can help the CGT industry “redefine safety, dosing and long-term efficacy.”

There is a need to reassure the safety of such products. In 2021, investigational cell and gene therapy products were responsible for approximately 40% of clinical holds.

Still, the scrutiny on cell and gene therapy trials may have a silver lining. “I think it is bringing the community together,” Zhang said. She added that cell and gene therapy developers are “an incredibly close-knit community.” The recent uptick in clinical trial holds “brings safety to the forefront of all of our minds and unites us.”

Toward single-cell analysis

Mission Bio says the ability of its Tapestri platform to offer single-cell analysis enables a deep characterization of biotherapeutics and collaboration with regulators to reduce the likelihood of adverse events linked to cell and gene therapy.

“At one point, I wondered, would I allow my children to participate in a clinical trial for cell and gene therapy,” Zhang said. Patients who participate in such trials are “potentially risking their lives to be part of this incredible revolution that can bring treatment to hundreds of millions,” she added. “It’s our responsibility to do the best we can to prevent that from happening — to preserve their lives,” she said.

The goal of cell and gene therapy is to save and improve lives — not to cause adverse events. “Every time an adverse event occurs [in cell and gene therapy space], it gives the entire community a determination to want to do better,” Zhang said.


Filed Under: Cell & gene therapy, Video features, Women in Pharma and Biotech
Tagged With: cell and gene therapy, microfluidics, Mission Bio, Mission Bio's Tapestri platform, oncology, Yan Zhang
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

How Thermo Fisher’s KingFisher PlasmidPro crunches hours of plasmid prep to 5 minutes hands-on
Can space help heal hearts? ISS study charts new path for stem cell therapy
MIT team designs gene circuits for tighter control in gene therapy study
Meet STITCHR, the retrotransposon-based gene editor that enables large, scarless DNA insertions
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE